Gain Therapeutics, Inc. — Director's Dealing 2021

Mar 30, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Gain Therapeutics, Inc. (GANX)
CIK: 0001819411
Period of Report: 2021-03-17

Reporting Person: Riley Jeffrey Scott (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option	$3.37	2031-01-22	Common Stock (10000)		Direct

Footnotes

F1: The option will be fully vested and exercisable on January 20, 2022